article thumbnail

And the Winners Are…PeDRA Announces 2023 Grant Recipients

The Dermatology Digest

Five investigators have received funding through the 2023 PeDRA Research Grants, Career Bridge Research Grant, Pediatric Alopecia Areata Challenge Grant, and Childhood Eczema Challenge Grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

article thumbnail

5-Year Safety Data Leaves Investigators Optimistic in Upadacitinib for AD Management

Dermatology Times

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Safety 74
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Don’t Miss Out: La Roche-Posay Calls for 2024 Young Investigator Grant Applicants, Announces 2023 Grant Winners

The Dermatology Digest

Meet La Roche-Posay’s 2023 Young Investigator Grant Winners… Drs. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

article thumbnail

Meet the 2023 NEA Grant Winners

The Dermatology Digest

The National Eczema Association (NEA) announced the recipients for its 2023 research grants. The 2023 research grantees include: The Champion Research Grant encourages researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema.

Eczema 36
article thumbnail

Fenbendazole Joe Tippens Protocol: A Simple Step-by-Step Guide (2023)

Aesthetics Advisor

Since fenbendazole is a veterinary medicine, and is not licensed for human use and there is no specific human safety data available. The similar human forms of this class of medications, mebendazole and albendazole, have been used for parasitic infections for many years and have a good safety record. chemotherapy?

Therapy 69
article thumbnail

Two-year Data: PsA Patients Taking Bimekizumab-bkzx (Bimzelx, UCB) Show Sustained Improvements

The Dermatology Digest

2023 For psoriatic arthritis patients, the new data demonstrated robust maintenance of clinical responses, including complete skin clearance (PASI100), minimal disease activity, improvements in joint pain, and patient reported outcomes to two years.

article thumbnail

FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar

The Dermatology Digest

The FDA’s approval of PYZCHIVA is based on a totality of evidence including analytical, non-clinical and clinical data demonstrating biosimilarity to Stelara, with no clinically meaningful differences in terms of safety, purity and potency. PYZCHIVA, developed by Samsung Bioepis, will be commercialized by Sandoz in the United States.